Clinical advances on danoprevir and triple therapy of danoprevir with Peg IFN and ribavirin regimen in treatment of chronic hepatitis C / 中华临床感染病杂志

ABSTRACT

So far, thirty-seven clinical trials of danoprevir in treatment of chronic hepatitis C (CHC)have been completed globally,in which more than 2 600 patients were involved.The clinical trials among Chinese patients with genotype 1 CHC showed that the sustained virologic response(SVR)rate reached to 97.0% after twelve-week treatment of danoprevir combined with PR regimen(Peg IFN and ribavirin), and the safety was good.